SCHEMBL1640608

SCHEMBL1640608

Nc1nc(-c2cccc(NC(=O)c3cc(F)ccc3F)c2)c(-c2ccnc(Cl)n2)s1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRAF P15056 5/20 0.47
FADS1 O60427 1/20 0.45
LCLAT1 Q6UWP7 2/20 0.45
TGFBR1 P36897 2/20 0.43
LMNA P02545 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
EGFR P00533 2/20 0.40
ATR Q13535 1/20 0.39
BTK Q06187 1/20 0.39
MAPT P10636 1/20 0.39
MAPK1 P28482 1/20 0.39
ERBB2 P04626 1/20 0.38
ABL1 P00519 1/20 0.38
PDGFRB P09619 1/20 0.38
BCR P11274 1/20 0.38
PDGFRA P16234 1/20 0.38
ESR1 P03372 1/20 0.38
ESRRG P62508 1/20 0.38
ESR2 Q92731 1/20 0.38
LCK P06239 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1641998 0.90 LCLAT1 (0.46) BRAFFADS1LCLAT1LMNASMN1; SMN2
SCHEMBL1640558 0.90 LCLAT1 (0.45) BRAFFADS1LCLAT1LMNASMN1; SMN2
SCHEMBL1639294 0.88 BRAF (0.49) BRAFTGFBR1LMNASMN1; SMN2EGFR
SCHEMBL1642305 0.86 LCLAT1 (0.43) BRAFFADS1LCLAT1LMNASMN1; SMN2
SCHEMBL1642023 0.86 LCLAT1 (0.47) BRAFFADS1LCLAT1LMNASMN1; SMN2
SCHEMBL1642021 0.82 ABL1 (0.51) BRAFEGFRABL1PDGFRBBCR
SCHEMBL12726468 0.82 ABL1 (0.47) BRAFLCLAT1EGFRMAPK1ABL1
SCHEMBL1641864 0.81 TGFBR1 (0.42) BRAFTGFBR1EGFR
SCHEMBL1643563 0.80 EGFR (0.47) BRAFEGFRBTKABL1PDGFRB
SCHEMBL1640550 0.80 BRAF (0.46) BRAFTGFBR1LMNASMN1; SMN2EGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110098296-A1 Thiazole And Oxazole Kinase Inhibitors GLAXOSMITHKLINE LLC 2011-04-28 US disclosed
US-20110098296-A1 Thiazole And Oxazole Kinase Inhibitors GLAXOSMITHKLINE LLC 2011-04-28 US disclosed
US-20110098296-A1 Thiazole And Oxazole Kinase Inhibitors GLAXOSMITHKLINE LLC 2011-04-28 US disclosed
WO-2009076140-A1 THIAZOLE AND OXAZOLE KINASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2009-06-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110098296-A1 Thiazole And Oxazole Kinase Inhibitors PDXK, MAP3K1, MAP4K2 BRAF 151/4885FADS1 4718/4885LCLAT1 2338/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.